The recall affects a lot that may lead to underdosing, posing risks primarily to infants and young children. Cipla has not received reports of adverse events related to this recall and is coordinating the return of the affected products.
Cipla Limited has informed the Exchange regarding a press release dated December 10, 2023, titled "Voluntary Nationwide Recall of one lot of Vigabatrin for Oral Solution, USP 500mg due to leaking sachets by InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company in USA".